top of page
Landing background.jpeg

Bridging the

Drug Discovery Path with Translatable Neuroscience

blue green wave lines.png

NeuCyte is an innovative biotechnology company focused on CNS drug discovery.

Based on its proprietary SynFire® technology for generating human iPSC-derived neurons, NeuCyte has developed a highly functional in vitro platform for target identification and validation, efficacy testing, neurotoxicity assessment, and disease modeling. The team is actively pursuing drug discovery programs on Alzheimer's disease, ALS, Epilepsy, Fragile X Syndrome and more.

AdobeStock_267809431_edited.jpg

Our Unique Approach
 

The high attrition rate of novel CNS drugs during clinical development has been a major challenge to the pharmaceutical industry. This is largely attributed to the lack of biologically relevant models to study functional links between target and phenotype.

NeuCyte’s mission is to accelerate and optimize CNS drug discovery by developing more predictive assays and platforms for phenotypic screening.

blue green wave lines.png

SynFire   Technology Platform
 

®

Based on the advantageous SynFire technology for generating human induced pluripotent stem cell (iPSC)-derived induced neuronal cells (iNs), NeuCyte has developed a proprietary in vitro human neural platform for complex electrophysiological and morphological readouts suited for target identification and validation, efficacy testing and neurotoxicity assessment.

 

Using patient-derived and genetically engineered defined neural cell types, NeuCyte builds unique cell-based assays for modeling neurological and neurodegenerative disorders.

Web_Movie_B4_3.gif

Drug Discovery Programs

With our proprietary technology platform and exciting collaborations, NeuCyte is actively pursuing drug discovery programs for several genetically defined neurological diseases.

blue green wave lines.png
blue green wave lines.png

Latest News

NeuCyte presents a scientific poster at the Alzheimer's Association International Conference

Unknown.png

Adam Caar

Developer

San Diego, California

July 31 - August 3, 2022.

Development of iPSC-derived Alzheimer Disease (AD) platforms for phenotypic screening

NeuCyte exhibits and presents at Society of Toxicology annual meeting in San Diego

SOT-AM22-HP-Tile-360x230b2_edited.png

Adam Caar

San Diego, California

March 29, 2022

Hui Liu, PhD, NeuCyte's Head of Drug Discovery presents: 

Exhibitor Hosted Session: Establishing an In Vitro Assay for Effectively Predicting Neurotoxicity Risk Using Human iPSC-Derived Neurons

Developer

NeuCyte and KIF1A.ORG Enter Collaboration Agreement

kif1a.png

Adam Caar

San Carlos, California, USA, August 17th, 2021 – NeuCyte, Inc., an innovative biotech company focused on developing novel treatments for neurological disorders, today announced that it has entered into a research collaboration agreement with KIF1A.ORG.

Developer

NeuCyte and Mount Sinai Enter Collaboration Agreement

mount sinai _edited.png

Adam Caar

Developer

San Carlos, California, USA, January 19, 2021 - NeuCyte, Inc., an innovative biotech company focused on developing novel treatments for neurological disorders, today announced that it has entered into a research collaboration agreement with the Seaver Autism Center for Research and Treatment at the Icahn School of Medicine at Mount Sinai.

Looking for an exciting and rewarding career opportunity?

NeuCyte-Logo_original_blue[37082].png

Adam Caar

Take on an exciting journey to accelerate and optimize drug discovery with fellow neuroscientists

Leave your mark, Improve lives

Developer

bottom of page